Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer

Video

Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.

Related Videos
Benjamin Levy, MD
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Saad J. Kenderian, MB, CHB
Jaime Schneider, MD, PhD
Benjamin Creelan, MD
Neel P. Chudgar, MD
Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine
Related Content
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
FDA

FDA Grants Fast Track Designation to PT217 for Extensive Stage Small Cell Lung Cancer

April 9th 2024
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
Suresh Senan, PhD

Consolidation Durvalumab Generates Survival Benefit in LS-SCLC

April 5th 2024
Article
Steve Worland, PhD

Tomivosertib Development in Frontline NSCLC Ending After Findings from KICKSTART Trial

April 4th 2024
Article